部份中文布洛芬赖氨酸处方资料（仅供参考）
英文药名：NEOPROFEN (ibuprofen lysine Injection)
中文药名：布洛芬赖氨酸静脉注射
生产厂家：Lundbeck Inc
药品介绍
批准日期：2006年4月13日 公司：Lundbeck Inc
neoprofen（布洛芬赖氨酸[ibuprofen lysine]）注射，静脉注射使用
1974年美国最初批准：
作用机理
布洛芬导致新生儿动脉导管未闭（PDA）闭合的作用机制尚不清楚。在成人中，布洛芬是前列腺素合成的抑制剂
适应症
neoprofen冰一nonsteroidal抗炎药物（表示两个重要clinically关闭动脉导管未闭（PDA）在早产儿婴幼儿weighing 500和1500克之间，谁是不超过32周妊娠年龄，当正常的医疗管理ineffective冰。临床试验是在传导时间和asymptomatic PDA。然而，后果超出了8周的治疗后，有没有评估；因此，治疗应该保留对幼儿与透明的证据一个显着clinically PDA。
剂量和管理
（三）冰道治疗剂量静脉管理
的初始剂量（10毫克/公斤（基于轻冰birth）随后市双剂量（5毫克/公斤，每天，在24和48小时
如果没有administer市场无尿或少尿（＜0.6毫升/公斤/小时）明显的冰在预定的时间在第二或第三次。
剂型和长处
20mg／2ml（10毫克/毫升）作为一种无防腐剂的透明无菌溶液中的L-赖氨酸盐（在一个2毫升的布洛芬单用瓶
contraindications
在neoprofen冰contraindicated preterm时间：与suspected感染或测试，这是untreated与先天性心脏病在谁的patency冰满意为必要的PDA肺或全身的血液流动与受损的肾功能，血小板减少症与凝血缺陷，或谁是出血
谁是与或有suspected大学necrotizing小肠结肠炎
precautions WARNINGS鸭有没有neoprofen assessed为neurodevelopmental鸭生长的结果
neoprofen坛年份可能感染的迹象。
neoprofen可以inhibit血小板聚集，和两个已经shown prolong出血时间在正常的成人受试者。
布洛芬已被两个位移shown胆红素从白蛋白结合的网站
neoprofen应该避免两个直辖carefully extravascular注射或泄漏
不良反应
最常见的不良反应（≥10%）是intraventricular脓毒症、贫血、出血、呼吸、消化道疾病，肾功能受损的皮肤，呼吸道感染，治疗，hypoglycemia，hypocalcemia失效，呼吸。
包装供应/储存和搬运
供应
NeoProfen（布洛芬赖氨酸）注射剂在处理过的透明玻璃一次性小瓶中分配，每个小瓶含有2毫升无菌溶液（NDC 55292-122-52）。溶液没有缓冲，不含防腐剂。每毫升含有17.1毫克/毫升（±）-布洛芬L-赖氨酸[相当于10毫克/毫升（±）-布洛芬]，溶于注射用水，USP。氯丙纶是在一个纸箱中提供的，其中包含3个一次性小瓶。
储存和搬运
储存在20–25°C（68–77°F）；允许偏移15–30°C（59–86°F）【见USP控制的室温】。避光。把小瓶用纸箱装起来，直到里面的东西用完。
*在具有二氧化硅涂层或聚合物涂层的玻璃小瓶中分配新的罗芬（布洛芬赖氨酸），该涂层可抑制布洛芬赖氨酸与未经处理的玻璃相互作用产生的微粒的形成。
完整资料附件：https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021903s010lbl.pdf
NEOPROFEN® (Ibuprofen lysine) Injection for intravenous use (into a vein)
Indications and Usage
NEOPROFEN is a prescription medication used to close a sufficiently concerning patent ductus arteriosus (PDA) in premature infants weighing between 500 and 1500 grams (1.10 – 3.30 pounds), who are no more than 32 weeks in gestational age, when usual medical management is ineffective. The clinical trial leading to approval of NEOPROFEN was conducted among infants with no apparent symptoms of PDA. However, the consequences from using NEOPROFEN beyond 8 weeks after treatment have not been eva luated; therefore, treatment should be reserved for infants with clear evidence of symptoms that are important signs of PDA.
Important Safety Information
NEOPROFEN should not be used in preterm infants:
With proven or suspected infection that is not treated
With heart disease that is present at birth in whom openness of the PDA is necessary for satisfactory lung or general body blood flow
With impaired kidney function
With  low blood platelet counts, problems with the body’s blood clotting process or who are bleeding
With or who are suspected of having a condition seen in some premature infants where portions of the bowel undergo tissue death
NEOPROFEN has not been studied for how the nerves grow and develop
NEOPROFEN may alter the usual signs of infection
NEOPROFEN can inhibit part of the sequence leading to the formation of a blood clot, and has been shown to prolong bleeding time in normal adults
Ibuprofen has been shown to displace bilirubin (a liver breakdown product) from binding sites on albumin (a protein in blood serum)
NEOPROFEN should be administered carefully to avoid injection outside of the vein or leakage from the vein
Most common adverse reactions (≥10%) are sepsis (a life-threatening complication of an infection), decreased amounts of healthy red blood cells or hemoglobin, bleeding into the fluid-filled areas of the brain, temporary suspension of breathing, disorders related to the stomach or intestines, impaired kidney function, respiratory infection, abnormal growth or appearance of the skin, low blood sugar, low blood calcium, inability of the lungs to perform their basic task of gas exchange